Please login to the form below

Not currently logged in
Email:
Password:

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

AZ’s MYSTIC survival data is in – and it’s a bust

AZ’s MYSTIC survival data is in – and it’s a bust

Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and ... In the meantime, AZ also has trials of Imfinzi

Latest news

  • Is AstraZeneca looking for its next CEO? Is AstraZeneca looking for its next CEO?

    Pangalos has helped oversee a renaissance in the company’s small molecule pipeline, with targeted lung cancer treatment Tagrisso its star growth product. ... This includes strong growth in China, key approvals for Imfinzi in stage III lung cancer and

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

  • Roche pulls EU Tecentriq/Avastin filing in kidney cancer Roche pulls EU Tecentriq/Avastin filing in kidney cancer

    little longer before it can bring it forward for RCC, the most common form of kidney cancer. ... line use of the pair in non-small cell lung cancer (NSCLC) based on the IMpower150 study, delaying its verdict by three months.

  • Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

    Tecentriq is already approved in the US for certain types of bladder cancer and lung cancer, but has seen sales growth slow of late due to strong competition from other immunotherapies ... The Swiss drug maker was hoping to gain another indication for

  • AZ says target of $45bn sales by 2023 still achievable AZ says target of $45bn sales by 2023 still achievable

    The cancer franchise was once again a standout, particularly Tagrisso (osimertinib) for EGFR-mutated non-small cell lung cancer (NSCLC) which grew 91% year-to-date and is now hitting the ... Lynparza (olaparib) for ovarian and breast cancer more than

More from news
Approximately 100 fully matching, plus 730 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the failure of two immunotherapies in the MYSTIC lung cancer trial last year – but the company ... The park is also home to the Cancer Research UK Institute, a

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA) ’s Priority Review pathway, ... AZ isn’t a frontrunner overall in lung cancer

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Made in China Made in China

    man who is diagnosed with cancer but finds himself unable to afford the Western medicine that could save his life. ... targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

More from intelligence
Approximately 1 fully matching, plus 41 partially matching documents found.

Latest appointments

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer. “

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

A reflection of ESMO
Client Relationship Director Fabienne Wild from Ashfield Meetings & Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO)....
OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....

Infographics